10 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp04678 | MHC Class I chain-related protein | MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETEEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTLYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA | Human | Immune response regulation | WST-8 assay | HepG2 | Hepatocellular carcinoma | MIC : >5 µg/mL |
| dbacp04679 | MHC Class I chain-related protein | MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFLSQNLETEEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTLYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHWQTFHVSAVAAAAIFVIIIFYVRCCKKKTSAAEGPELVSLQVLDQHPVGTSDHRDATQLGFQPLMSDLGSTGSTEGA | Human | Immune response regulation | WST-8 assay | PLC/PRF/5 | Hepatocellular carcinoma | MIC : >5 µg/mL |
| dbacp06913 | AC-P19M | FAKKLAKLKKKLAKLAKKR | Synthetic analogue of AC-P19 | Inhibition of cell signalling | WST-8 assay | A-549 | Lung Cancer | IC50 = 9.84 µM |
| dbacp06914 | AC-P19M | FAKKLAKLKKKLAKLAKKR | Synthetic analogue of AC-P19 | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 6.29 µM |
| dbacp06915 | AC-P19 | FAKKLAKLKKKLAKLALAL | Synthetic | Inhibition of cell signalling | WST-8 assay | A-549 | Lung Cancer | IC50 = 52.14 µM |
| dbacp06916 | AC-P19 | FAKKLAKLKKKLAKLALAL | Synthetic | Inhibition of cell signalling | WST-8 assay | H-460 | Lung Cancer | IC50 = 49.08 µM |
| dbacp06975 | C16-E4Y | EEEEY | Synthetic | Inhibition of cell signalling | WST-8 assay | A-431 | Skin Cancer | 10 % cell viability at 0.05 wt % |
| dbacp06976 | C16-E4Y | EEEEY | Synthetic | Inhibition of cell signalling | WST-8 assay | HeLa | Cervical Cancer | 60% cell viability at 0.05 wt % |
| dbacp06977 | C16-E4Y | EEEEY | Synthetic | Inhibition of cell signalling | WST-8 assay | HepG-2 | Liver Cancer | 50 % cell viability at 0.05 wt % |
| dbacp06978 | C16-E4Y | EEEEY | Synthetic | Inhibition of cell signalling | WST-8 assay | MCF-7 | Breast Cancer | 50 % cell viability at 0.05 wt % |